Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
2.995
-0.015 (-0.50%)
Jul 24, 2026, 2:20 PM EDT - Market open
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenue of $6.47M in the quarter ending March 31, 2026, a decrease of -56.11%. This brings the company's revenue in the last twelve months to $66.41M, up 11.07% year-over-year. In the year 2025, Recursion Pharmaceuticals had annual revenue of $74.68M with 26.92% growth.
Revenue (ttm)
$66.41M
Revenue Growth
+11.07%
P/S Ratio
23.94
Revenue / Employee
$110,680
Employees
600
Market Cap
1.59B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 74.68M | 15.84M | 26.92% |
| Dec 31, 2024 | 58.84M | 14.26M | 32.00% |
| Dec 31, 2023 | 44.58M | 4.73M | 11.88% |
| Dec 31, 2022 | 39.84M | 29.67M | 291.46% |
| Dec 31, 2021 | 10.18M | 6.22M | 156.89% |
| Dec 31, 2020 | 3.96M | 1.64M | 70.85% |
| Dec 31, 2019 | 2.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.18B |
| Innoviva | 420.69M |
| AnaptysBio | 232.39M |
| Zymeworks | 81.26M |
| AbCellera Biologics | 79.21M |
| Septerna | 72.26M |
| Intellia Therapeutics | 66.09M |
| Vir Biotechnology | 65.50M |
RXRX News
- 4 weeks ago - Cathie Wood’s ARK Investment buys 260K shares of Recursion Pharmaceuticals today - TheFly
- 5 weeks ago - Recursion Pharmaceuticals Transcript: AGM 2026 - Transcripts
- 6 weeks ago - Recursion Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Recursion to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules - GlobeNewsWire
- 2 months ago - Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City - GlobeNewsWire
- 2 months ago - Recursion Pharmaceuticals price target raised to $5.50 from $5 at Morgan Stanley - TheFly
- 2 months ago - Recursion Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts